[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:b-cell-non-hodgkin-lymphoma:cd19-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"B-Cell Non-Hodgkin Lymphoma","CD19 Gene",10,[8,16,23,29,35,41,47,54,60,67],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT04544592","UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL",[12],"Phase 1\u002FPhase 2","RECRUITING","2026-08-26T02:18:15.214990Z","2026-05-05T02:43:28.281463Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT05801913","Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma",[20],"Phase 1","2026-08-26T02:16:44.178623Z","2026-05-05T02:43:27.275760Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT07283679","Phase I\u002FII Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma",[12],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:27.977643Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT04892277","CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed\u002FRefractory B Cell Malignancies",[20],"2026-08-26T02:18:05.435729Z","2026-05-05T02:43:27.592999Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT05432635","Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma",[20],"2026-08-26T02:16:07.529922Z","2026-04-29T02:57:57.084734Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":45,"content_modified":46},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[20],"2026-08-26T02:16:59.895916Z","2026-07-19T19:36:05.125264Z",{"nct_id":48,"title":49,"phases":50,"status":13,"updated_at":52,"content_modified":53},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[51],"Phase 2","2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05773040","A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas",[20],"2026-08-26T02:19:30.857183Z","2026-05-05T02:35:31.752653Z",{"nct_id":61,"title":62,"phases":63,"status":64,"updated_at":65,"content_modified":66},"NCT07168486","CD19.20.22 CAR T-cells for Patients With Relapsed\u002FRefractory B-Cell Lymphomas",[20],"ENROLLING_BY_INVITATION","2026-08-26T02:19:19.975067Z","2026-06-16T05:54:07.870155Z",{"nct_id":68,"title":69,"phases":70,"status":71,"updated_at":72,"content_modified":73},"NCT05421663","A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma",[12],"ACTIVE_NOT_RECRUITING","2026-08-03T03:30:50.548292Z","2026-05-05T02:43:29.152099Z"]